SGLT2 & GLP-1 therapies: Real-world use, mechanisms and safety

P06_Dapagliflozin Therapy: Effects on Glycemic Control, Weight Loss, and Cardiovascular Health in Diabetic and Non-Diabetic Patients

Read More P06_Dapagliflozin Therapy: Effects on Glycemic Control, Weight Loss, and Cardiovascular Health in Diabetic and Non-Diabetic Patients
P07_Safety profile of GLP1 receptor agonists

Read More P07_Safety profile of GLP1 receptor agonists
P08_Effect of sodium-glucose cotransporter-2 inhibitors on telomeres length in patients with type 2 diabetes mellitus with and without chronic kidney disease

Read More P08_Effect of sodium-glucose cotransporter-2 inhibitors on telomeres length in patients with type 2 diabetes mellitus with and without chronic kidney disease
P09_Is there a link between GLP-1 receptor agonists and the risk of pancreatitis?

Read More P09_Is there a link between GLP-1 receptor agonists and the risk of pancreatitis?
P10_An analysis of sodium glucose co-transporter-2 inhibitors� usage amongst old-aged individuals

Read More P10_An analysis of sodium glucose co-transporter-2 inhibitors� usage amongst old-aged individuals